LncRNA SNHG4 Promotes Malignant Biological Behaviors and Immune Escape of Colorectal Cancer Cells by Regulating the MiR-144-3p/MET Axis
Overview
Affiliations
Objective: This study aimed to explore the underlying mechanism of long noncoding RNA (lncRNA) SNHG4 regulating MET to participate in the malignant biologic behaviors and immune escape of colorectal cancer (CRC) by sponging miR-144-3p.
Methods: CRC tissues were collected and the expression levels of lncRNA SNHG4, miR-144-3p, and MET were detected by quantitative real-time PCR (qRT-PCR). Then, the localization of lncRNA SNHG4 was studied by fluorescence in situ hybridization (FISH), and the regulatory relationship among lncRNA SNHG4, miR-144-3p, and MET was verified by dual-luciferase reporter assay. Next, cell counting kit-8 (CCK-8), Clone formation assay, and Transwell migration assay were carried out to evaluate cell proliferation, colony formation, and invasion, respectively. Flow cytometry was performed to evaluate cell apoptosis. Western blotting was applied to semi-quantify the expression levels of MET and PD-L1 in cells.
Results: LncRNA SNHG4 expression was upregulated in CRC tissues. Knockdown of lncRNA SNHG4 suppressed the proliferation, colony formation and invasion of CRC cells (all P<0.05). LncRNA SNHG4 directly regulated miR-144-3p, by which either lncRNA SNHG4 knockdown or miR-144-3p overexpression can inhibit CD4+ T cell apoptosis (both P<0.05) to suppress immune escape. Either overexpression of lncRNA SNHG4 or knockdown of miR-144-3p activated PD-1/PD-L1 and induced CD4+ T cell apoptosis (both P<0.05). LncRNA SNHG4 targeted and regulated MET through the regulation of miR-144-3p, while overexpression of MET can partially reverse the effect of lncRNA SNHG4 knockdown on CD4+ T cells.
Conclusion: LncRNA SNHG4 sponges miR-144-3p and upregulates MET to promote the proliferation, colony formation, invasion, and immune escape of CRC cells, leading to the progression of CRC.
Chen Z, Wu Z, Wu M, Zhang Y, Hou S, Wang X Biochem Genet. 2024; .
PMID: 39688781 DOI: 10.1007/s10528-024-11000-3.
Wang S, Bai Y, Ma J, Qiao L, Zhang M Front Pharmacol. 2024; 15:1442227.
PMID: 39512820 PMC: 11540796. DOI: 10.3389/fphar.2024.1442227.
Zhang Y, Sui P, Zhong C, Liu J J Cancer. 2024; 15(8):2260-2275.
PMID: 38495502 PMC: 10937287. DOI: 10.7150/jca.92558.
Zabeti Touchaei A, Vahidi S Cancer Cell Int. 2024; 24(1):102.
PMID: 38462628 PMC: 10926683. DOI: 10.1186/s12935-024-03293-6.
Song B, Chen Y BMC Pulm Med. 2023; 23(1):513.
PMID: 38114929 PMC: 10731904. DOI: 10.1186/s12890-023-02818-5.